Taltz (ixekizumab) — Medica

Initial criteria

• age ≥ 6 years
• EITHER trial of at least one traditional systemic agent for ≥ 3 months (e.g., methotrexate, cyclosporine, acitretin, or PUVA) unless intolerant OR contraindication to methotrexate determined by prescriber
• prescribed by or in consultation with a dermatologist

Reauthorization criteria

• therapy established for at least 3 months
• beneficial clinical response defined as improvement from baseline in at least one of: body surface area, erythema, induration/thickness, and/or scale of psoriatic areas
• improvement in at least one symptom (e.g., decreased pain, itching, or burning)

Approval duration

initial 3 months, reauthorization 1 year